In order to meet significantly higher demand from Novo Nordisk A/S for raw materials for the production of medicines to fight chronic diseases, Novo Nordisk Pharmatech A/S is building a new factory at Ådalen 16 in Køge.
In March 2023, Novo Nordisk Pharmatech announced the purchase of a 47,000 m² site in Køge, with the purpose of expanding the current production at Københavnsvej 216 in Køge. Novo Nordisk Pharmatech is now investing 1.5 billion Danish kroner in approximately 8,000 m² facility containing production, storage, office, and laboratory on this site. The facility is expected to be ready for production in 2027. The new plant, located at Ådalen 16, will primarily supply raw materials for Novo Nordisk’s production of medicine to fight critical chronic diseases.
‘This is the largest investment in Novo Nordisk Pharmatech’s 75-year history. We are in a period of growth. In accordance with our growth strategy, we are expanding our production to ensure an even more robust and reliable delivery of our products. The location in Køge is ideal, as we can draw on the extensive know-how we have at our current factory – and furthermore, the infrastructure is optimal, with Køge Nord station so close to our new site,’ says Ulla Grove Krogsgaard Thomsen, CEO Novo Nordisk Pharmatech A/S.
It is expected that the new factory will create around 50 new jobs.
Novo Nordisk Pharmatech is focusing on both capacity and sustainability in this project. Drawing from the experiences of the current production at Københavnsvej, it has been decided to reuse important elements for production, including regenerating raw materials, thereby reducing Novo Nordisk Pharmatech’s CO2 footprint by around 60%. Solar panels will be installed in the parking lot, and the building will also be constructed using sustainable materials.
‘In the building design, we have placed great emphasis on it blending into the natural area by Ådalen, and have, among other things, decided to construct the office building using wood. This results in CO2 savings and is more sustainable,’ says Andreas Kyhn Brejnholt, Project Director at Novo Nordisk Pharmatech.
The area allows for expansions to support Novo Nordisk Pharmatech’s future strategy of launching new products for the global Pharmaceutical and Biopharmaceutical industries. In early 2024, office facilities for project and construction work were established at Ådalen.
